Abstracts tagged "Cardiovascular"

Abstract Number: 1280 • ACR Convergence 2023
Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Joshua Baker², Brian Sauer³, Grant Cannon⁴, Gary Kunkel⁵, Bryce Binstadt⁶, Amy Joseph⁷, K Wysham⁸, Aleksander Lenert⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee¹, Geoffrey Thiele¹, Ted R Mikuls¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Minnesota, Minneapolis, MN, ⁷Washington University / St. Louis VA, St. Louis, MO, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Iowa, Iowa City, IA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹University of Texas Southwestern Medical Center, Dallas, TX, ¹²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The risk of aortic stenosis is increased in people with RA and valvular heart disease (VHD) is among the most over-represented causes of cardiovascular…
Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Hsin Yen Liu¹, Jiandong Su², Dennisse Bonilla², Sara Duaibes², Juan Pablo Diaz Martinez³ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…
Abstract Number: 2106 • ACR Convergence 2023
Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls
Stephen Oakley¹, Samantha Stott¹, Kerri Gill¹, Chan Virgil¹, Lyanne Weston² and Theo de Malmanche¹, ¹John Hunter Hospital, New Lambton, Australia, ²Australian Red Cross Blood Service, Alexandria, Australia
Background/Purpose: The risk of developing ACPA+RA, predictors of severity and causes of excess cardiovascular disease (CVD) are incompletely understood. We have observed that RA patients…
Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Natalie McCormick¹, Kehuan Lin², Chio Yokose³, Na Lu⁴, Yuqing Zhang¹ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
Abstract Number: 0419 • ACR Convergence 2023
No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors
Romy Hansildaar¹, Reinder Raadsen¹, Maaike Heslinga² and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-fold higher risk of venous thromboembolism (VTE) compared with the general population. The immune system and hemostatic…
Abstract Number: 0634 • ACR Convergence 2023
Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Raychel Barallon¹, Gene-Siew Ngian¹, Diane Apostolopoulos¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens⁴, Susanna Proudman⁵, Mandana Nikpour⁶ and Joanne Sahhar¹, ¹Monash Health and Monash University, Clayton, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ⁴Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
Abstract Number: 0898 • ACR Convergence 2023
The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction
Kennedy Hawkins, Marice McCrorey, C. Alex Colvert, Kristine DeLeon-Pennell, Melissa Cunningham and Justin Van Beusecum, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by autoantibody formation and immune complex deposition in target organs. While it is known that…
Abstract Number: 1283 • ACR Convergence 2023
Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness
Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Victor Beltran³, Angel Arias Peralta⁴, Jesus Alberto Cardenas-De la Garza⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: The atherogenic index of plasma (AIP) is a novel marker to identify cardiovascular disease. Recently, AIP was reported to be related to long-term cardiovascular…
Abstract Number: 1604 • ACR Convergence 2023
First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Jonathan Thaler¹, Yasaman Ahmadzadeh², Danieli Andrade³, leslie skeith⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Denis WAHL¹⁴, Maria Gerosa¹⁵, Guilherme De Jesús¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Laura Andreoli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁷, Guillermo Pons-Estel²⁸, Rohan Willis²⁹, Ali Duarte-Garcia³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³², Doruk Erkan¹ and On Behalf Of APS ACTION³³, ¹Hospital for Special Surgery, New York, NY, ²Roger Williams Medical Center, Providence, RI, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Milan, Milano, Italy, ¹⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷University of Michigan, Ann Arbor, MI, ²⁸CREAR, Rosario, Argentina, ²⁹University of Texas Medical Branch, Galveston, TX, ³⁰Mayo Clinic, Rochester, MN, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³³on behalf of APS ACTION, New York, NY
Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
Abstract Number: 2118 • ACR Convergence 2023
New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry
Robert Spandorfer¹, Kevin Kane², George Reed², Dimitrios Pappas², Joel Kremer², Jeffrey Curtis³ and Iris Navarro-Millán⁴, ¹Hospital for Special Surgery, Brooklyn, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
Abstract Number: 2430 • ACR Convergence 2023
Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim¹, Bryant England³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Punyasha Roul³, Ted R Mikuls⁷, Shirley Cohen-Mekelburg¹, Daniel Clauw⁸, Wyndy Wiitala², Rodney Hayward¹, Jeremy Sussman¹ and Akbar Waljee⁹, ¹VA Ann Arbor; University of Michigan, Ann Arbor, MI, ²VA Ann Arbor, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁹VA Ann Arbor, University of Michigan, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events…
Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², K Wysham³, Jean liew⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Zoe Brown¹, Dylan Hansen², Wendy Stevens³, Nava Ferdowsi⁴, laura ross⁵, Alannah Quinlivan⁶, Joanne Sahhar⁷, Gene-Siew Ngian⁷, Diane Apostolopoulos⁷, Jennifer G Walker⁸, Susanna Proudman⁹, Gim Gee Teng¹⁰, Andrea Hsiu Ling Low¹¹, Kathleen Morrisroe¹² and Mandana Nikpour¹³, ¹The University of Melbourne, Armadale, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁴St Vincents Hospital, Kew, Australia, ⁵St. Vincent's Hospital Melbourne, Fitzroy, Australia, ⁶St Vincent's Hospital Melbourne, Highett, Australia, ⁷Monash Health and Monash University, Clayton, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ¹⁰Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ¹¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ¹²The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹³The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…
Abstract Number: 0901 • ACR Convergence 2023
Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus
Jaya Krishnan¹, Néstor de la Visitación¹, Jonathan Williams¹, Leslie Crofford² and David Patrick³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].